U.S. Court in DC Rejects Novartis’ Challenge to FDA Approval of Generic Version of Heart Failure Drug Entresto
- October 18, 2024
The U.S. District Court for the District of Columbia declined October 15 to upend the Food and Drug Administration’s (FDA’s) approval of a generic version of Novartis Pharmaceuticals Corp.’s heart failure drug Entresto.
ARTICLE TAGS
You must be logged in to access this content.